Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, with news flow that reflects activity across its Affordable Medicines, Specialty, and AvKARE segments. This page aggregates company-specific coverage so readers can follow how Amneal’s development, manufacturing, and distribution efforts translate into regulatory milestones, clinical results, and financial performance.
News about Amneal frequently centers on U.S. FDA approvals and regulatory updates. Recent announcements include approvals for denosumab biosimilars referencing Prolia and XGEVA, epinephrine injection in single- and multi-dose vials for hospitals, iohexol injection as a first generic version of Omnipaque, albuterol sulfate inhalation aerosol as a generic equivalent of PROAIR HFA, and cyclosporine ophthalmic emulsion 0.05% as a generic equivalent of RESTASIS. These items illustrate the company’s focus on complex injectables, biosimilars, respiratory therapies, and ophthalmic products within its Affordable Medicines segment.
In the Specialty segment, news coverage highlights branded CNS and endocrine therapies, particularly CREXONT for Parkinson’s disease. Amneal has reported positive interim Phase 4 ELEVATE-PD results and emphasizes CREXONT’s role in improving motor symptom control and "Good On" time. The company also reports on collaborations, such as a research collaboration and option agreement with KeifeRx to advance KFRX06, a brain-penetrant LRRK2 program for Parkinson’s disease.
Investors and analysts will also find financial results and capital markets updates, including quarterly earnings releases, guidance updates, and details of term loan and senior secured notes financings. Governance and corporate events, such as participation in healthcare investor conferences and board changes, are disclosed through press releases and Form 8-K filings.
For users tracking AMRX, this news feed provides a centralized view of regulatory decisions, product launches, clinical data, financing transactions, and strategic collaborations that shape Amneal’s business across its three segments.
Amneal (NASDAQ: AMRX) reported Q1 2026 net revenue $723M, GAAP net income $62M and diluted EPS $0.19; adjusted EBITDA was $202M and adjusted diluted EPS was $0.27. Specialty revenue rose 23%; Affordable Medicines rose 2%.
The company affirmed its raised 2026 guidance: net revenue $3.05B–$3.15B, adjusted EBITDA $740M–$770M, adjusted diluted EPS $0.95–$1.05, and operating cash flow $350M–$400M.
Amneal Pharmaceuticals (NASDAQ: AMRX) agreed to acquire Kashiv BioSciences to create a fully integrated global biosimilars platform. The transaction combines Kashiv’s development and manufacturing with Amneal’s commercial scale, aims to accelerate the biosimilar pipeline, and is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.
The combined company will target expanded patient access to affordable biologics and strengthened U.S. commercial positioning.
Amneal (Nasdaq: AMRX) agreed to acquire Kashiv BioSciences for $750 million upfront (cash and equity) plus up to $350 million in milestone payments, forming an integrated global biosimilars platform. The deal targets >$300B of biologics loss-of-exclusivity and is expected to close in H2 2026, subject to approvals.
Amneal reported preliminary Q1 2026 results: consolidated revenue $723M (+4%), gross margin 44.3% (+750 bps), net income $78M, and raised 2026 standalone guidance including adjusted EBITDA $740M–$770M.
Amneal (Nasdaq: AMRX) announced positive interim Phase 4 ELEVATE-PD results (first 111 patients, six weeks) showing clinically meaningful benefits after switching to CREXONT. Patients switching from RYTARY gained +3.07 hours daily “Good On” time and nearly doubled continuous “Good On” intervals to 6.58 hours.
Across prior therapies CREXONT increased “Good On” time, reduced “Off” time, and improved MDS-UPDRS scores; common adverse events included dizziness and nausea.
Amneal (Nasdaq: AMRX) launched two metered-dose inhalation (MDI) generics in the U.S. on April 14, 2026: albuterol sulfate inhalation aerosol (90 mcg) and beclomethasone dipropionate HFA inhalation aerosol (40/80 mcg), both FDA-approved in 2025.
These are Amneal’s first U.S. MDI launches, manufactured at its dedicated inhalation facility in Ireland. According to IQVIA U.S. annual sales data, 12-month sales through Feb 2026 were about $1.5B for albuterol and $321M for beclomethasone, indicating meaningful market opportunity.
Amneal (NASDAQ:AMRX) launched bimatoprost ophthalmic solution 0.01% on April 9, 2026 in 2.5 mL, 5 mL and 7.5 mL sizes. The product is the generic equivalent of LUMIGAN and is indicated to reduce elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
Amneal said the launch supports its Affordable Medicines segment and cites IQVIA U.S. annual sales of approximately $719 million for the 12 months ended February 2026.
Amneal (NASDAQ: AMRX) will release its first quarter 2026 financial results on Friday, May 1, 2026 before market open. The company will host a live audio webcast at 8:30 a.m. ET, accessible via the Investor Relations site, with a conference line and replay posted after the call.
Dial-in details and the access code 458312872 are provided for conference access; registration is available on the Investor Relations website.
Amneal (Nasdaq: AMRX) announced a $2 million donation to multiple patient assistance foundations to support people living with Parkinson’s disease during Parkinson’s Awareness Month (April 2026).
The funds will help eligible patients cover out-of-pocket costs for FDA-approved Parkinson’s medications; Amneal said it has donated $3.5 million to Parkinson’s causes over the past two years and will continue advocacy, education, and Spanish-language resources.
Amneal (Nasdaq: AMRX) announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 11:00 AM ET in Miami, FL.
A live webcast and a replay will be available on Amneal's Investor Relations website.
Amneal (Nasdaq: AMRX) reported Q4 2025 net revenue of $814 million and GAAP net income of $35 million (diluted EPS $0.11). Full‑year 2025 net revenue was $3.02 billion with GAAP net income of $72 million and adjusted diluted EPS of $0.83. The company provided 2026 guidance of $3.05–3.15 billion revenue, $720–760 million adjusted EBITDA and $0.93–1.03 adjusted diluted EPS.
The release highlights Specialty growth (CREXONT, UNITHROID), new branded launches, and AvKARE strength, while management reiterated assumptions behind non‑GAAP reconciliations and provided a Feb. 27, 2026 webcast for investors.